Factors in the gut microbiome that may improve treatment for patients with gut damage or gastrointestinal disease were recently detailed in paper in the journal Microbiome by researchers from the Snyder Institute for Chronic Diseases at the University of Calgary and the University of Colorado. Using a mouse model, the researchers’ new findings improved the understanding of the underlying mechanisms that help regulate the enteric nervous system (ENS).
Author: Praveen Suthrum
The United States Multi-Society Task Force (MSTF) on colorectal cancer (CRC) has released updated screening recommendations, endorsing 45 as the age to start average-risk CRC screening. These recommendations solidify our announcement in May 2021 supporting the U.S. Preventive Services Task Force in lowering the screening age. The MSTF, which is comprised of representatives from AGA, ACG and ASGE, updated the 2017 CRC screening recommendations, focusing on the specific questions of when to start and when to stop CRC screening in average-risk individuals.
The CMS final rule regarding physician payment, clinical labor prices, critical care services and telehealth services for fiscal year 2022 has drawn mixed reactions from medical groups. Some of the rule’s components exacerbate concerns brought on by the COVID-19 pandemic while others alleviate them, the groups said.
Private equity and artificial intelligence are two of the most controversial issues in gastroenterology, according to five gastroenterologists who spoke to Becker’s ASC Review. Editor’s note: Responses were lightly edited for clarity and brevity. Samuel Giordano, MD, of Cooper University Health Care (Willingboro, N.J.): I think the most controversial trend in gastroenterology today is navigating and implementing the usage of artificial intelligence technology to help assist endoscopists with polyp detection. It is clear, based on the early data, that there is an opportunity for practice improvement and evolution, but the tricky part is the implementation. There are several companies that…
In this podcast episode, Joe Rubinsztain, MD, the CEO of ChronWell, discusses his path to becoming a doctorpreneur, the creation of gMed and more.
Gastro Health, a national leading medical group specializing in digestive and liver health, has signed a definitive agreement to partner with Digestive Care Center based in North Miami. The deal is scheduled to close on December 1. The Digestive Care Center is home to Eduardo Kofman, MD, a board-certified gastroenterologist, who founded the practice in 1997 in Texas and moved it to North Miami in 2008. Dr. Kofman and his team are committed to providing each patient personalized, efficient and reliable care.
Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal health, today announced the closing of a Series B financing, raising a total of $105 million through a combination of debt and equity. The round is led by previous investors Lightchain Capital and NT Investments. Other investors in the round include Morningside Ventures, Labcorp, Cultivation Capital, BioGenerator Ventures, and Innovatus Capital Partners. “We are extremely pleased to secure this financing with strong support from our previous and new investors. It reflects their confidence in our ability to address the significant unmet need within the colorectal…
Nonalcoholic fatty liver disease (NAFLD) has become the most common form of liver disease in the United states, with its prevalence rising in conjunction with obesity rates. A lack of screening guidelines for fatty liver means it is most often diagnosed incidentally once patients show elevated liver enzymes or an echogenic liver on abdominal ultrasound. A recent study aims to improve the evaluation of fatty liver in abdominal imaging and identify factors that predict significant fibrosis and specialist referrals. Patients with NAFLD are classified into 2 subgroups. NALFD is considered benign with low likelihood of progressive liver disease, and nonalcoholic…
– Motilent’s clinically-validated AI software has received 510k clearance from the US FDA – Currently, 62 million people in the US are diagnosed with a digestive disorder annually[1], causing an ever-growing burden on healthcare services globally – Almost $136BN is spent on GI therapies[2] annually but some drugs, e.g. those used in Inflammatory Bowel Disease, have a 60% failure rate within 1 year. It can take months or years to confirm if a therapy is no longer working for a patient. – New collaboration with AI-powered solutions provider Nuance Communications will allow US healthcare clinics using innovative GIQuant software to…
Using a novel clinical pathway integrated into the electronic medical record, researchers were able to identify patients with inflammatory bowel disease who were overdue for medical follow-ups, according to data presented at the ACG Annual Scientific Meeting. “Both the unpredictable relapsing nature of IBD as well as discordance between subjective symptoms and underlying levels of inflammation make patients less likely to attend routine office visits, and we may miss critical opportunities to improve disease control and avoid complications,” Matthew K. Schroeder, MD, a chief resident in internal medicine at UT Southwestern Medical Center, said during a virtual poster presentation. “We…